< Back to previous page
Researcher
Ignace Vergote
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Jan 2012 → Today
Projects
1 - 10 of 12
- Defining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → TodayFunding: FWO Strategic Basic Research Grant
- Comprehensive genomic and transcriptomic analysis of high grade serous ovarian cancer using single-cell RNA-sequencing.From1 Jan 2019 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
- Searching for new leads in the diagnosis of ovarian cancerFrom1 Oct 2017 → 30 Sep 2021Funding: Foundations, funds and other with scientific goal
- Comprehensive transcriptomic analysis of high-grade serous tubo-ovarian carcinoma using single-cell RNA-sequencing.From1 Mar 2017 → 5 Jul 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- From Never to Always Events: in search for mango-momentsFrom1 Nov 2016 → 31 Oct 2018Funding: Nonprofit institution or equivalents
- FIRST PET-MR: Flmeish interuniversity research simultaneous time-of-flight PET-MR scanner.From14 Aug 2014 → 13 Feb 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Flemish interuniversity simultaneous time-of-flight PET-MR scanner for research.From14 Aug 2014 → 13 Feb 2019Funding: Hercules - Large scale research infrastructure
- A drug strategy targeting stabilised mutant p53 to fight metastatic plantinum-resistant ovarian cancer.From1 Oct 2013 → 31 Mar 2019Funding: General Activities (Annex IV)
- Dendritic cell immunotherapy in serous ovarian cancer.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
Publications
1 - 10 of 691
- Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.(2022)
Authors: Els Van Nieuwenhuysen, Sileny Han, Siel Olbrecht, Patrick Neven, Diether Lambrechts, Toon Van Gorp, Ignace Vergote
Pages: 14 - 22 - European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer(2022)
Authors: Ignace Vergote, Diether Lambrechts
Pages: 276 - 287Number of pages: 12 - Survival with Cemiplimab in Recurrent Cervical Cancer(2022)
Authors: Ignace Vergote
Pages: 544 - 555Number of pages: 12 - Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial(2022)
Authors: Ignace Vergote
Pages: 254 - 264Number of pages: 11 - Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer(2021)
Authors: Ignace Vergote
Pages: 2123 - 2131Number of pages: 9 - Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer(2021)
Authors: Christine De Bruyn, Jolien Ceusters, Thaïs Baert, Ann Vankerckhoven, Roxanne Wouters, Dominique Schols, Dirk Timmerman, Ignace Vergote, An Coosemans
Number of pages: 13 - Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer-A Study of the OVCAD Consortium(2021)
Authors: Toon Van Gorp, Ignace Vergote
Number of pages: 12 - European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma(2021)
Authors: Ignace Vergote
Pages: 1508 - 1529Number of pages: 22 - MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma(2021)
Authors: Diether Lambrechts, Liselore Loverix, Siel Olbrecht, Ignace Vergote
Pages: 855 - 871Number of pages: 17 - Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II(2021)
Authors: Ignace Vergote
Pages: 3623 - +Number of pages: 11